Odyssey Therapeutics, Inc. Marketable Securities, Unrealized Gain (Loss)
Odyssey Therapeutics, Inc. (ODTX) reported Marketable Securities, Unrealized Gain (Loss) of $644.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2026-08-06
- Odyssey Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2026-06-30 was $464.00K.
- Odyssey Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2026-03-31 was $180.00K, a 318.60% increase year-over-year.
- Odyssey Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2025-06-30 was -$8.00K.
- Odyssey Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2025-03-31 was $43.00K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month |
|---|---|---|
| 2026-06-30 | $464.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $644.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $180.00K 10-Q · filed 2026-06-17 | |
| 2025-06-30 | -$8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $35.00K 10-Q · filed 2026-08-06 |
| 2025-03-31 | $43.00K 10-Q · filed 2026-06-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |